🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

5 recruiting trials

for Solid Tumors Refractory to Standard Therapy

Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors NCT06940349Phase 1, Phase 21 site📍 Petah Tikva Rabin Medical Center · Tests: Palbociclib, Sunitinib SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors NCT06873659Phase 111 sites📍 Beijing📍 Beijing📍 Beijing Qurgen Inc. · Tests: SON-DP Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies NCT07309770Phase 21 site📍 Shanghai Sheng Zhang · Tests: SHR-A1811, Trastuzumab Rezetecan A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. NCT06883539Phase 12 sites📍 Taichung📍 Tainan LaunXP Biomedical Co., Ltd. · Tests: LXP1788 is administered intravenously via Port-A AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors NCT06911333Phase 1, Phase 23 sites📍 Seongnam-si📍 Seoul📍 Seoul Avelos Therapeutics Inc. · Tests: AD1208
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy